Science and Research
LASER LIGHT-01: Evaluation of the R:GEN Laser System as an Intervention in Subjects with Early Stages of Age-related Macular Degeneration (AMD) for Safety and Exploratory Efficacy Outcomes
The main aim of this study is to evaluate the safety and tolerability of the R:GEN Laser System in participants with the early stages of age-related macular degeneration (AMD).
Overview
Currently there is no specific treatment available for the early changes of AMD. The R:GEN Laser System from Lutronic Vision Inc. may offer a potentially effective treatment.
The main aim of the LASER LIGHT-01 study is to evaluate the safety and tolerability of the R:GEN Laser System in participants with the early stages of AMD.
People in Australia over 50 years of age with the early stages of AMD in both eyes may qualify to participate in this study.
All participants will be required to attend a screening visit before receiving R:GEN laser treatment in both eyes at the baseline visit and the 6 month visit. Participants will be evaluated at 6 and 12 months from the baseline visit.
The study duration for each participant is approximately one year.
Referrals from healthcare practitioners of suitable patients are welcome.
For further information about this study, please contact the Macular Research Unit on (03) 9929 8388 or email amd-studies@cera.org.au.
- Principal Investigator
Professor Robyn Guymer AM
Currently there is no specific treatment available for the early changes of AMD. The R:GEN Laser System from Lutronic Vision Inc. may offer a potentially effective treatment.
The main aim of the LASER LIGHT-01 study is to evaluate the safety and tolerability of the R:GEN Laser System in participants with the early stages of AMD.
People in Australia over 50 years of age with the early stages of AMD in both eyes may qualify to participate in this study.
All participants will be required to attend a screening visit before receiving R:GEN laser treatment in both eyes at the baseline visit and the 6 month visit. Participants will be evaluated at 6 and 12 months from the baseline visit.
The study duration for each participant is approximately one year.
Referrals from healthcare practitioners of suitable patients are welcome.
For further information about this study, please contact the Macular Research Unit on (03) 9929 8388 or email amd-studies@cera.org.au.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.